arrow
A

Ann M. Moyer

College of American Pathologists
H指数:34
被引数:4,094

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Functional Assignment of TPMT and NUDT15 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel

临床功能赋值:TPMT和NUDT15等位基因由临床药物基因组学实施联盟药物基因筛选专家小组完成

2026-08-110
OAAI
Rapid Germline Testing with Hair Root Bulb-Derived DNA for Hereditary Predisposition and Inherited Marrow Failure States

利用毛发根球来源的DNA进行快速生殖系检测,以评估遗传易感性和获得性骨髓衰竭状态

2026-04-070
OAAI
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update
2026-01-310
OAAI
Ten years of RASGRP2-related platelet disorder: Implications for molecular haematology and diagnostics

十年RASGRP2相关血小板疾病:对分子血液学和诊断的意义

2025-09-010
PRE
Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

美国药物基因组学实施进展:障碍侵蚀与遗留挑战

2025-06-040
OAAI
Clinical Outcomes and Treatment Strategies of Adult Transplant-Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High-Risk Criteria

成人移植相关性血栓性微血管病变的临床结局与治疗策略:定义和危险因素标准的调和及其外部验证

2025-03-060
OA
Clinicopathologic, Proteomic and Outcome Characteristics of Renal Apolipoprotein C-II Amyloidosis: A Case Series

肾载脂蛋白C-II淀粉样变性的临床病理、蛋白质组学和预后特征:一个病例系列

2025-03-010
PRE
Genotype-Guided P2Y12 Inhibitor Monotherapy Within 7 Days of Percutaneous Coronary Intervention in High Bleeding Risk Patients: The CHAMP Trial - A Pilot Study and Safety Assessment

基因型指导的P2Y12抑制剂单药治疗在经皮冠状动脉介入治疗后7天内高出血风险患者中的应用:CHAMP试验——一项 пилот研究及安全性评估

2025-01-010
PRE